Live Investor Briefing Prescient Therapeutics

Prescient Therapeutics (ASX: PTX)

Live Investor Briefing

Register for an Upcoming Webcast

Please join Prescient CEO and managing director Steven Yatomi-Clarke for an investor briefing.

In this session, Steven will discuss:

  • How PTX is taking the cancer treatment conversation from ‘fight’ to ‘cure’
  • How the company can potentially make any CAR-T developer’s therapies more effective, cheaper and safer
  • How its modular platform allows PTX to partner with any CAR-T developer giving them a ‘shovels to the gold rush’ position

It will be a fascinating look into why Prescient’s highly scalable business model gives them multiple shots on goal in oncology.

This is a live and interactive online session, and participants are encouraged to ask questions.  Spots are limited, so secure yours today.

Book Your Spot

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Corporate provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.


Steven Yatomi-Clarke (Speak feature)

Steven Yatomi-Clarke

CEO and Managing Director

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.